Home Heroes De Novo Discovery Gene Scan CDx Pathway ♻️ Repurposing 🚦 Gates Models Quantum 🧪 Wet Lab Schedules 🎛️ Control 🧬 CIFOG 📈 Milestones 🧬 BioBrain 🧠 NPEAD Architecture 🔬 RODE 🧠 Cortex-R Workspace 🧠 V2 🧠 V3 📦 Knowledge 💰 Revenue 🧪 Tests 📊 Costs 📚 Datasets

🧬 PPP3CC — Discovery Report

📄 Autonomous discovery by Cortex · 2026-05-22

Gene	PPP3CC
Full Name	Protein Phosphatase 3 Catalytic Subunit Gamma
Target Protein	PPP3CC_protein
Cancer Type	Prostate
Grade	A+
Priority	HIGH
Stage	lead_candidate
Novelty	FIRST-IN-CLASS (0 ChEMBL)

🧬 BioBrain ⚖️ Decisions

Scientific Hypothesis

"PPP3CC/calcineurin dephosphorylates NFAT driving immune evasion and proliferation. Selective PPP3CC inhibition blocks tumor NFAT without systemic immunosuppression."

Mechanism of Action

Pathway: PPP3CC → calcineurin → NFAT → immune evasion + proliferation

Clinical Angle: Targeted calcineurin inhibition for immune-evasive prostate cancer

Docking Results

Metric	Value
Best Vina Score	-9.0 kcal/mol
Best Molecule (SMILES)	`O=C(Nc1ccc2ncccc2c1)c1ccc(F)c(NC(=O)C2CC2)c1`
Molecular Weight	339.4 Da
QED / DCSAL	0.815
Molecules Tested	32
Docking Method	smina (real GPU, g4dn.xlarge)
Receptor Source	AlphaFold v4

5-Dimension Scoring

🎯 Binding: 0.9 🔬 Pathway: 0.87 💡 Innovation: 0.95 💊 Therapy: 0.88 ⭐ Novelty: 1.0 🧬 BioBrain ⚖️ Decisions

Total Score: —

Governance

PQM Status	ISSUED
QCM Trust	1.0
Ledger Logged	✅ SHA-256 hash chain
Evidence ID	RO-PPP3CC
Authority	marcus_60 (sole override)

Conclusion

PPP3CC is a FIRST-IN-CLASS (0 ChEMBL) target with A+ grade binding affinity (-9.0 kcal/mol). The mechanistic hypothesis (PPP3CC → calcineurin → NFAT → immune evasion + proliferation) provides a clear therapeutic rationale for Prostate. Targeted calcineurin inhibition for immune-evasive prostate cancer. Recommended for wet lab validation.

MindNetQ Inc. — Governed Intelligence for Precision Medicine
Report generated by Cortex autonomous discovery pipeline. All decisions ledger-hashed.